Advanced Biologics (known commercially as Biologica Technologies) has merged with Isto Biologics. The transaction will integrate Advanced Biologics’ proprietary products into Isto’s growing portfolio of allografts found within their Influx line.
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC. SPARC is a novel inductive bone matrix that stemmed from Advanced Biologics’ proprietary tissue processing method used in their OsseoGen allograft. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
Past transactions in Isto’s history include the 2016 acquisition of Arteriocyte Medical Systems and the 2022 acquisition of TheraCell.
“We are thrilled for our entire Advanced Biologics/Biologica team to join forces with Isto Biologics,” said Amit Govil, President of Advanced Biologics. “This merger brings together the clinical, commercial, and research-driven expertise of both companies and a shared commitment to help patients heal faster.”
“With this merger, our combined team is now elevated with greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market,” said Don Brown, CEO of Isto Biologics.
Advanced Biologics (known commercially as Biologica Technologies) has merged with Isto Biologics. The transaction will integrate Advanced Biologics’ proprietary products into Isto’s growing portfolio of allografts found within their Influx line.
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020,...
Advanced Biologics (known commercially as Biologica Technologies) has merged with Isto Biologics. The transaction will integrate Advanced Biologics’ proprietary products into Isto’s growing portfolio of allografts found within their Influx line.
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC. SPARC is a novel inductive bone matrix that stemmed from Advanced Biologics’ proprietary tissue processing method used in their OsseoGen allograft. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
Past transactions in Isto’s history include the 2016 acquisition of Arteriocyte Medical Systems and the 2022 acquisition of TheraCell.
“We are thrilled for our entire Advanced Biologics/Biologica team to join forces with Isto Biologics,” said Amit Govil, President of Advanced Biologics. “This merger brings together the clinical, commercial, and research-driven expertise of both companies and a shared commitment to help patients heal faster.”
“With this merger, our combined team is now elevated with greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market,” said Don Brown, CEO of Isto Biologics.
Copy to clipboard 
